Biological enzyme that catalyzes formation of three-membered or four-membered oxygen-containing heterocyclic structure of taxane molecule, gene, biological material, and use of biological enzyme, gene and biological material

By identifying and applying taxane C4-C20 oxetane to form enzyme TOT, catalyzing the formation of oxetane-like structures of taxane molecules, the problems of high production cost and low yield in the existing technology are solved, and the problem of high production cost and low yield of paclitaxel is achieved. Efficient paclitaxel synthesis and intermediate production.

WO2024230462A1PCT designated stage expired Publication Date: 2024-11-14AGRICULTURAL GENOMICS INSTITUTE AT SHENZHEN CHINESE ACADEMY OF AGRICULTURAL SCIENCES (SHENZHEN BRANCH GUANGDONG LABORATORY FOR LINGNAN MODERN AGRICULTURE) +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/089061
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-05
Filing Date
2024-04-22
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

The existing paclitaxel production methods rely on plant extraction and chemical synthesis, which cannot meet market demand, and the paclitaxel synthesis pathway is insufficient to analyze, making it difficult to improve yield.

Method used

Identification and provision of a taxane C4-C20 oxetane-forming enzyme TOT, which can catalyze the formation of oxetane-like structures of taxane molecules, used to synthesize paclitaxel and intermediates, and improve through genetic engineering and metabolic engineering strategies. Yield.

Benefits of technology

The analysis of biosynthesis pathways of compounds such as paclitaxel has been significantly promoted, reducing production costs, solving the problems of expensive drugs and in short supply, and providing new genetic resources to increase production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024089061_14112024_PF_FP_ABST
    Figure CN2024089061_14112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to the technical field of synthetic biology. Provided in the present invention are a biological enzyme that catalyzes the formation of a three-membered or four-membered oxygen-containing heterocyclic structure of a taxane molecule, a gene, a biological material, and the use of the biological enzyme, gene and biological material. The biological enzyme comprises: at least one of amino acid sequences as shown in SEQ ID NOs: 25-48; a fusion protein thereof; a mutant protein thereof; and a homologous protein thereof. The provided biological enzyme can catalyze the formation of a three-membered or four-membered oxygen-containing heterocyclic structure of a taxane molecule, thereby providing new gene resources in terms of increasing the yield of related compounds having an oxetane ring group and an oxirane ring group such as paclitaxel and completing the synthetic pathway thereof; and the nucleotide sequence can be used for modifying a chassis host by means of genetic engineering and metabolic engineering strategies, and producing drugs such as paclitaxel and intermediates thereof, and has significant economic and social values.
Need to check novelty before this filing date? Find Prior Art

Description

Biological enzymes, genes, biomaterials and their applications for catalyzing the formation of ternary or quaternary oxygen heterocyclic structures of taxane molecules Technical Field

[0001] The present application relates to the field of synthetic biology technology, and in particular to biological enzymes, genes, biomaterials and their applications for catalyzing the formation of ternary or quaternary oxygen heterocyclic structures of taxane molecules. Background Art

[0002] Taxanes are a series of derivatives synthesized by structurally modifying the anti-tumor active ingredients isolated from plants. Taxanes primarily include paclitaxel, docetaxel, cabazitaxel, and derivatives with a taxane backbone.

[0003] Paclitaxel is a diterpenoid alkaloid with the structural formula shown below:

[0004] Paclitaxel was first isolated from the bark of Taxus brevifolia and is now widely used in the clinical treatment of various cancers.

[0005] Currently, obtaining paclitaxel APIs primarily relies on plant extraction, chemical / semi-chemical synthesis, and biosynthesis, but none of these approaches can meet market demand. Semi-chemical synthesis involves extracting the natural precursors baccatin III and 10-deacetylbaccatin III (10-DAB) from leaves, followed by chemical synthesis of paclitaxel. However, this method still relies on plant-derived precursors, constrained by plant resources and unable to fully address supply issues. In commercial production, cell culture has been used to produce paclitaxel APIs. However, initial paclitaxel yields from bark cells are too low, and due to insufficient understanding of the paclitaxel biosynthesis pathway, conventional metabolic engineering strategies have been difficult to significantly increase paclitaxel yields. Therefore, identifying the key enzymes involved in paclitaxel biosynthesis, and then employing synthetic biology and metabolic engineering strategies to reconstruct the paclitaxel biosynthesis pathway in plants or microorganisms, and mass-producing paclitaxel in cell culture has the potential to completely address the paclitaxel supply challenge.

[0006] Oxetanes, as strained four-membered heterocyclic rings, can serve as both stabilizing groups in bioactive compounds and reactive synthetic intermediates. Due to their drug-like properties, oxetanes are frequently used in drug development as replacements for geminal dimethyl and carbonyl groups, exhibiting improved physicochemical properties. Natural oxetane-containing compounds (OCCs) possess enormous structural diversity and complexity, offering unique advantages and opportunities for modern drug discovery and development. Over 600 different OCCs have been discovered in animals, plants, and microorganisms, with the majority being produced by plants. Three reaction mechanisms have been identified for the biosynthesis of natural oxetane skeletons: [2+2] cycloaddition, ring contraction, and ring expansion. The [2+2] cycloaddition and ring contraction mechanisms have been identified in animals and microorganisms. In contrast, ring expansion reactions are currently only known in plants. However, the enzymes that catalyze the ring expansion reaction and oxetane formation are unknown.

[0007] The Taxaceae family holds the largest number of OCCs found in plants, with the most famous example being paclitaxel. Paclitaxel possesses a complex 6-8-6 tricyclic carbon skeleton with nine stereocenters, a distinct oxetane ring group, and a phenylisoserine chain. Since the structure of paclitaxel was first reported in 1971, the formation of the oxetane ring in yew plants has garnered considerable attention from synthetic and computational chemists. The biosynthesis of paclitaxel proceeds through a 19-step process involving hydroxylation, acetylation, oxidation, and epoxidation. The epoxidation reaction is the most critical step, and the enzymes involved have yet to be identified.

[0008] Therefore, the discovery and identification of the taxane C4-C20 oxetane-forming enzyme is a crucial step in improving the entire paclitaxel synthesis pathway, and is also necessary for the future heterologous reconstruction of the paclitaxel synthesis pathway.

[0009] Summary of the Invention

[0010] In view of this, the present application provides a bioenzyme, nucleic acid molecule, biomaterial and its application for catalyzing the formation of a three-membered or four-membered oxygen heterocyclic structure of a taxane molecule. The bioenzyme can be used to synthesize oxygen-containing heterocyclic compounds (such as paclitaxel and its intermediates).

[0011] In order to achieve the above-mentioned invention objectives, this application provides the following technical solutions:

[0012] The present application provides a biological enzyme comprising at least one of the following sequences:

[0013] a1) at least one of the amino acid sequences shown in SEQ ID NOs: 25 to 48;

[0014] a2) a fusion protein obtained by linking a tag to the N-terminus and / or C-terminus of at least one of the amino acid sequences shown in SEQ ID NOs: 25 to 48;

[0015] a3) a protein having the same function obtained by substitution and / or deletion and / or addition of one or more amino acid residues in at least one of the amino acid sequences of SEQ ID NOs: 25 to 48;

[0016] a4) A protein having at least 60% homology to at least one of the amino acid sequences shown in SEQ ID NOs: 25 to 48 and having the same function.

[0017] The inventors of the present application, through large-scale resource screening, isolated a taxane C4-C20 oxetane-forming enzyme gene from Taxus chinensis var. maire, which is named TOT in the present application, and successfully obtained the gene-encoded protein (i.e., taxane C4-C20 oxetane-forming enzyme, also named TOT in the present invention). Functional analysis revealed that TOT could catalyze the substrate taxa-4(20),11-diene-2α,5α,7β,9α,10β,13α-hexaol-hexa-acetate (taxadiene-hexaol-hexaacetate, compound (1)) or its derivatives to produce two products, of which 1-dehydroxybaccatin IV (1-dehydroxybaccatin IV, compound (2)) was the main product and the other product was baccatin I (baccatin I, compound (3)). The taxane C4-C20 oxetane-forming enzyme gene TOT provided genetic resources for the production of 1-dehydroxybaccatin IV and baccatin I.

[0018] The present application creatively identifies a taxane C4-C20 oxetane-forming enzyme from Taxus chinensis. The taxane C4-C20 oxetane-forming enzyme TOT provides a synthetic pathway for the production of 1-dehydroxybaccatin IV and baccatin I.

[0019] Furthermore, the present application obtained homologous proteins and mutants of TOT, demonstrating that the homologous proteins and mutants can also catalyze the production of 1-dehydroxybaccatin IV and baccatin I.

[0020] Furthermore, the catalytic reaction technology can guide the synthesis of compounds having an oxetane ring group and / or compounds having an oxirane ring group.

[0021] In a specific embodiment of the present application, in the fusion protein obtained by connecting tags to the N-terminus and / or C-terminus of the amino acid sequence shown in SEQ ID NOs: 25 to 48, the connection tags are not specifically limited and can be added according to the purpose of use. For example, the following can be selected but are not limited to: HIS, GST, Flag, MBP, HA, c-Myc, eGFP, eYFP, and eCFP.

[0022] In an embodiment of the present application, the protein in a3) is a protein in which one or more (for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) amino acid residues are added, deleted, or replaced in the amino acid sequence shown in a1) and has the same biological enzyme activity function.

[0023] In an embodiment of the present application, the protein in a3) is a protein in which one or more (for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) amino acid residues are added, deleted, or replaced in the amino acid sequence shown in a1) and has similar or better biological enzyme activity function.

[0024] In a specific embodiment of the present application, the protein in a3) is a mutant of the amino acid sequence shown in a1), and the mutant includes at least one of V237A, P167A, Q187A, Q6A, V129A, I172A, S314A, V319A, Q381A, E313A, V205A, R50A, S500A, P428A, H249A, S310A, K259A, R269A, M177A, D361A, V382A, I347A, V371A, G448A, P454AA, P490A, I285A, T410A, T231A, K360A, G455A, and K94A. The above amino acids are represented by single-letter abbreviations, and the Chinese names, English names, and English abbreviations of the amino acids are commonly used in the art.

[0025] In an embodiment of the present application, the protein in a4) is a protein having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% homology to the amino acid sequence shown in a1) and having the same function.

[0026] Optionally, a4) the amino acid sequence is derived from Taxus, including but not limited to European yew Taxus baccata L., short-leaved yew Taxus brevifolia Nutt., limestone yew Taxus calcicola LMGao & Mich. Taxus canadensis Marshall, Taxus chinensis (Pilg.) Rehd., Taxus contorta Griff., Taxus cuspidata Siebold & Zucc., Taxus floridana Nutt.ex Chapm., Taxus florinii Spjut, Taxus globosa Schltdl., Taxus mairei (Lemée & Lév.) SYHu, Taxus phytonii Spjut, Taxus sumatrana (Miq.) de Laub., Taxus wallichiana Zucc., Taxus Huangshan type, Taxus Emei type, Taxus Qinling type., Taxus yunnanensis WCCheng & LKFu, Taxus media Rehder, Taxus hunnewelliana Rehder, etc.

[0027] In a specific embodiment of the present application, the homologous sequences of the amino acid sequence shown in SEQ ID NO: 25 are the amino acid sequences shown in SEQ ID NO: 26 to 48. The homologous sequences shown in SEQ ID NO: 26 to 48 have a homology of 64.8% to 100% with the amino acid sequence shown in SEQ ID NO: 25.

[0028] In a specific embodiment of the present application, the above-mentioned biological enzyme is an isolated biological enzyme.

[0029] The present application also provides a gene encoding the above-mentioned biological enzyme, which includes at least one of the following sequences:

[0030] b1) at least one of the nucleotide sequences shown in SEQ ID NOs: 1 to 24;

[0031] b2) a complementary sequence, a degenerate sequence, or a homologous sequence of at least one of the nucleotide sequences of SEQ ID NOs: 1 to 24, wherein a homologous sequence is a nucleotide sequence having at least 75% identity with the nucleotide sequences of SEQ ID NOs: 1 to 24;

[0032] b3) A nucleotide sequence that hybridizes with the nucleotide sequence shown in b1) or b2) under stringent conditions and is capable of encoding a protein with the same function.

[0033] In an embodiment of the present application, the gene is a nucleic acid molecule.

[0034] Optionally, the nucleic acid molecule is a synthetic and / or isolated nucleic acid molecule.

[0035] In the embodiment of the present application, the complementary sequence is a complementary sequence formed according to the principle of base complementary pairing, and the complementary sequence can be an incomplete complementary sequence or a complete complementary sequence having the same function as the nucleotide sequence shown in b1).

[0036] In the embodiments of the present application, a degenerate sequence means that after changing one or more nucleotides in the nucleotide sequence shown in b1), the type of amino acid encoded by the changed nucleotide sequence position remains unchanged, and the function and expression level of the gene are not affected.

[0037] In an embodiment of the present application, a homologous sequence is a nucleotide sequence that is at least 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% homologous to the nucleotide sequence shown in b1) and has the same function, such as a mutant gene, allele or derivative.

[0038] Optionally, b2) the nucleotide sequence of the nucleic acid molecule is derived from Taxus, including but not limited to European yew Taxus baccata L., short-leaved yew Taxus brevifolia Nutt., limestone yew Taxus calcicola LMGao & Mich. Taxus canadensis Marshall, Taxus chinensis (Pilg.) Rehd., Taxus contorta Griff., Taxus cuspidata Siebold & Zucc., Taxus floridana Nutt.ex Chapm., Taxus florinii Spjut, Taxus globosa Schltdl., Taxus mairei (Lemée & Lév.) SYHu, Taxus phytonii Spjut, Taxus sumatrana (Miq.) de Laub., Taxus wallichiana Zucc., Taxus Huangshan type, Taxus Emei type, Taxus Qinling type., Taxus yunnanensis WCCheng & LKFu, Taxus media Rehder, Taxus hunnewelliana Rehder, etc.

[0039] Illustratively, "stringent conditions" refer to conditions under which a probe will hybridize to its target sequence to a detectable extent exceeding hybridization to other sequences (e.g., at least 2 times background). Stringent conditions are sequence-dependent and vary depending on the circumstances. By controlling the stringency of hybridization and / or washing conditions, a target sequence that is 100% complementary to the probe can be identified. Alternatively, stringent conditions can be adjusted to allow for some sequence mismatches, such that a lower degree of similarity is detected.

[0040] In a specific embodiment of the present application, the homologous sequences of the nucleotide sequence shown in SEQ ID NO: 1 are the nucleotide sequences shown in SEQ ID NO: 2 to 24. The homologous sequences shown in SEQ ID NO: 2 to 24 have a homology of 77.9% to 100% with the nucleotide sequence shown in SEQ ID NO: 1.

[0041] The present application provides a biomaterial, which is any one of the following c1) to c4):

[0042] c1) an expression cassette containing the above gene;

[0043] c2) a recombinant vector containing the above gene or the expression cassette of c1);

[0044] c3) a recombinant microorganism containing at least one of the above-mentioned genes, c1) expression cassettes, and c2) recombinant vectors;

[0045] c4) Recombinant plant cells and / or recombinant animal cells containing at least one of the above-mentioned genes, c1) expression cassettes, c2) recombinant vectors, and c3) recombinant microorganisms.

[0046] In an embodiment of the present application, the recombinant plant cells and / or recombinant animal cells include non-biologically transformed (non-biologically transformed, i.e., produced by non-substantially biological methods) recombinant plant cells and / or recombinant animal cells.

[0047] In an embodiment of the present application, the expression cassette in c1) further comprises a promoter operably linked to the above-mentioned nucleic acid molecule. Optionally, the expression cassette in c1) further comprises other regulatory elements, such as enhancers, leader sequences, transposons, terminators, marker genes, etc.

[0048] In the embodiments of the present application, the type of recombinant vector in c2) is not specifically limited, and a suitable vector can be selected as needed. For example, the vector includes but is not limited to pFastBac1, pYES2, pYES2.1, pESC-Ura, pESC-Trp, pESC-Leu, pESC-His, pGEX2T, pTAex3, pUSA, pYMB0, pHT43, pET28b, pIJ702, pUCP19, pYMB03, or pHT43, preferably pESC-Ura.

[0049] In an embodiment of the present application, in the recombinant microorganism of c3), the microbial chassis includes but is not limited to at least one of Streptomyces, Pseudomonas, Bacillus, yeast cells, and Escherichia coli.

[0050] In an embodiment of the present application, the microorganisms in c3) include bacteria and / or fungi.

[0051] In the embodiments of the present application, bacteria include but are not limited to Escherichia cells, Lactobacillus cells, Lactococcus cells, Corynebacterium bacteria, Acetobacter bacteria, Acinetobacter bacteria, Pseudomonas cells, Streptomyces cells, Bacillus cells, Staphylococcus cells, Agrobacterium cells, and yew endophytes, such as Escherichia coli, Bacillus subtilis, Agrobacterium tumefaciens, Agrobacterium rhizogenes, Lactococcus lactis, Bacillus cereus, Pseudomonas fluorescens, and the like.In some embodiments, bacterial cells such as Escherichia spp., Streptomyces spp., Zymonas spp., Acetobacter spp., Citrobacter spp., Synechocystis spp., Rhizobium spp., Clostridium spp., Corynebacterium spp., Streptococcus spp., Xanthomonas spp., Lactobacillus spp., Lactococcus spp., Bacillus spp., Alcaligenes spp., Pseudomonas spp. spp.), Aeromonas spp., Azotobacter spp., Comamonas spp., Mycobacterium spp., Rhodococcus spp., Gluconobacter spp., Ralstonia spp., Acidithiobacillus spp., Microlunatus spp., Geobacter spp., Geobacillus spp., Arthrobacter spp., Flavobacterium spp., Serratia spp., Saccharopolyspora spp., Thermus spp.), Stenotrophomonas spp., Chromobacterium spp., Sinorhizobium spp., Saccharopolyspora spp., Agrobacterium spp., and Pantoea spp. The bacterial cell can be a Gram-negative cell, such as an E. coli cell, or a Gram-positive cell, such as a Bacillus species.

[0052] In an embodiment of the present application, the fungus includes but is not limited to yeast, filamentous fungi or mushrooms.

[0053] In a specific embodiment of the present application, yeast includes but is not limited to Saccharomyces cerevisiae, Schizosaccharomyces pombe, Yarrowia lipolytica, Candida utilis, Pichia pastoris, Kluyveromyces lactis, Hansenula polymorpha, Candida boidinii, A. adeninetolytica, Phaffia rhodozyma, and Candida albicans. Yeast cells are, for example, Saccharomyces spp., Schizosaccharomyces spp., Pichia spp., Paffia spp., Kluyveromyces spp., Candida spp., Talaromyces spp., Brettanomyces spp., Pachysolen spp., Debaryomyces spp., Yarrowia spp., and industrial polyploid yeast strains. Preferably, the yeast strain is a S. cerevisiae strain or a Yarrowia strain.

[0054] In a specific embodiment of the present application, filamentous fungi include but are not limited to Monascus, Aspergillus oryzae, Aspergillus niger, Aspergillus flavus, and Penicillium. Fungi are, for example, Aspergillus spp., Penicillium spp., Fusarium spp., Rhizopus spp., Acremonium spp., Neurospora spp., Sordaria spp., Magnaporthe spp., Allomyces spp., Ustilago spp., Botrytis spp., and Trichoderma spp.

[0055] The present application also provides an engineered strain comprising at least one of the above-mentioned nucleic acid molecule, expression cassette, and vector. In an embodiment of the present application, the engineered strain may be an engineered yeast strain or an engineered Escherichia coli strain.

[0056] The present application also provides a yeast engineering strain, which comprises at least one of the above-mentioned genes, expression cassettes, and recombinant vectors.

[0057] In a specific embodiment of the present application, the recombinant microorganism in c3) is a Saccharomyces cerevisiae containing a pESC-Ura::TOT plasmid. TOT in the pESC-Ura::TOT plasmid refers to the nucleotide sequence shown in b1) to b3).

[0058] In an embodiment of the present application, the recombinant plant cell of c4), the plant cell chassis includes but is not limited to at least one of yew cells, tobacco cells, white yew cells, Artemisia annua cells, Arabidopsis cells, Physcomitrella patens cells, Marchantia polymorpha cells, and algae cells.

[0059] In an embodiment of the present application, the plant cells of c4) include but are not limited to tobacco cells, white yew cells, Artemisia annua cells, Arabidopsis cells, Physcomitrella patens cells, liverwort cells, tomato cells, ginseng cells, cotton cells, sugarcane cells, potato cells, corn cells, wheat cells, rice cells, radish cells, lettuce cells, algae cells, etc., and the plant cells include protoplasts, suspension cells, etc.

[0060] In an embodiment of the present application, the algae cells include but are not limited to at least one of cyanobacteria, green algae, Synechococcus, Synechococcus elongatus, Synechocystis, Anabaena, Chlamydomonas, and Chlamydomonas reinhardtii.

[0061] In an embodiment of the present application, the recombinant animal cell of c4), the animal cell chassis includes but is not limited to insect cells, mammalian cells, fruit fly cells, nematode cells, and fish cells.

[0062] In an embodiment of the present application, the animal cells in c4) include but are not limited to at least one of insect cells, mammalian cells, nematode cells, and fish cells.

[0063] In a specific embodiment of the present application, insect cells include but are not limited to S2 Drosophila cells or Sf9 cells.

[0064] In a specific embodiment of the present application, mammalian cells include, but are not limited to, fibroblasts, lymphocytes, epithelial cells, and myeloblasts, such as HEK293 cells, CHO cells, COS cells, BHK cells, HeLa cells, Chinese hamster ovary cells, Vero cells, SP2 / 0 cells, NS / 0 myeloma cells, mini-hamster kidney cells, human B cells, human Jurkat T cells, neurons, CV-1 / EBNA cells, L cells, 3T3 cells, HEPG2 cells, and MDCK cells.

[0065] In a specific embodiment of the present application, fish cells include but are not limited to zebrafish cells.

[0066] In certain embodiments of the present application, the recombinant plant cells or recombinant animal cells express biological enzymes and produce target products through cell culture, which does not include developing the recombinant cells or recombinant animal cells into complete plants or animals.

[0067] In the above-mentioned biomaterials, methods for introducing genes, expression cassettes, and recombinant vectors into host cells in vivo and in vitro include, but are not limited to, electroporation, polyethylene glycol (PEG) transformation, lipofection, heat shock, calcium phosphate precipitation, virus-mediated, and microinjection. Host cells include microorganisms, plant cells, and / or animal cells.

[0068] The present application also provides a method for producing a host cell, which comprises transforming the host cell with at least one of the above-mentioned nucleic acid molecules, expression cassettes in biological materials or vectors.

[0069] In an embodiment of the present application, the host cell includes a microbial cell, a plant cell, an animal cell and / or an algae cell.

[0070] The present application also provides a method for producing a plant or a plant cell, which comprises transforming the plant or the plant cell with at least one of the above-mentioned nucleic acid molecules, expression cassettes in biological materials or vectors.

[0071] The present application provides a method for expressing the above-mentioned biological enzyme, wherein the TOT gene of the present application, or at least one of its expression cassette and recombinant vector, is transferred into microbial cells to allow the microbial cells to express the biological enzyme.

[0072] The present application provides another method for expressing the above-mentioned biological enzyme, wherein the TOT gene of the present application, or at least one of its expression cassette, recombinant vector, or recombinant microorganism, is transferred into plant cells or animal cells to allow the plant cells or animal cells to express the biological enzyme.

[0073] The present application provides a method for producing the above-mentioned biological enzyme, comprising: transforming the above-mentioned nucleic acid molecule, or at least one of the expression cassettes and vectors in the biological material into a host cell, so that the host cell produces the biological enzyme.

[0074] In an embodiment of the present application, the host cell includes a microbial cell, a plant cell, an animal cell and / or an algae cell.

[0075] The present application provides the use of any one of the above-mentioned biological enzymes, nucleic acid molecules or biological materials in the synthesis of oxygen-containing heterocyclic compounds, which include compounds having an oxetane ring group and / or compounds having an oxirane ring group.

[0076] In an embodiment of the present application, the compound having an oxetane ring group includes a taxane compound, and / or an intermediate thereof;

[0077] Preferably, the taxane compound includes but is not limited to at least one of paclitaxel and its derivatives, docetaxel and its derivatives, cabazitaxel and its derivatives;

[0078] Preferably, the taxane compound intermediate includes but is not limited to at least one of 1-dehydroxybaccatin IV and its derivatives, baccatin III and its derivatives, and 10-deacetylbaccatin III and its derivatives.

[0079] In an embodiment of the present application, the compound having an oxirane ring group includes at least one of baccatin I and its derivatives, taxumairol C and its derivatives, and taxuchin A and its derivatives.

[0080] The present application also provides a method for synthesizing an oxygen-containing heterocyclic compound in vivo or in vitro, using a taxane compound containing a 5α-acetoxy-4,20-alkenyl group or a taxane compound containing a 5α-hydroxy-4,20-alkenyl group as a substrate, and synthesizing the oxygen-containing heterocyclic compound under the catalysis of the above-mentioned biological enzyme;

[0081] The oxygen-containing heterocyclic compound includes a compound having an oxetane ring group and / or a compound having an oxirane ring group.

[0082] In an embodiment of the present application, the substrate includes but is not limited to at least one of taxadiene-hexol-hexaacetate, taxadiene-2α,5α,7β,9β,10β,13α-hexol-5α-acetate, 5α-acetate-Taxuspine F, taxadiene-hexol-tetraacetate, and Taxuspine F.

[0083] In the embodiments of the present application, in vivo includes within microorganisms, within plant cells and / or within animal cells.

[0084] In the embodiment of the present application, in vivo includes within algal cells.

[0085] In an embodiment of the present application, synthesizing an oxygen-containing heterocyclic compound in vivo comprises transferring at least one of the aforementioned genes, expression cassettes, recombinant vectors, and recombinant microorganisms into plant cells or animal cells, causing the plant cells or animal cells to express the biological enzyme of the present application; and synthesizing the oxygen-containing heterocyclic compound using a taxane compound containing a 5α-acetoxy-4,20-alkenyl group or a taxane compound containing a 5α-hydroxy-4,20-alkenyl group as a substrate under the catalytic action of the biological enzyme.

[0086] In an embodiment of the present application, synthesizing an oxygen-containing heterocyclic compound in vivo comprises transforming a host cell with the aforementioned nucleic acid molecule, or at least one of the expression cassettes and vectors in a biological material, so that the host cell produces the biological enzyme; and synthesizing the oxygen-containing heterocyclic compound under the catalytic action of the biological enzyme using a taxane compound containing a 5α-acetoxy-4,20-alkenyl group or a taxane compound containing a 5α-hydroxy-4,20-alkenyl group as a substrate.

[0087] Optionally, the substrate is produced in microbial cells, algal cells, plant cells and / or animal cells.

[0088] Optionally, the substrate may be artificially added additionally.

[0089] The present application also provides a plant or a plant part thereof, wherein the plant is one of the following plants:

[0090] (d1) transgenic plants containing the above nucleic acid molecules;

[0091] (d2) plants grown from the above plant cells;

[0092] (d3) Plants produced by the above method;

[0093] (d4) progeny formed by self-pollination of any one of the plants in (d1) to (d3), and plants grown from the progeny;

[0094] (d5) offspring formed by hybridizing any plant of (d1) to (d3) with other varieties, and plants grown from the offspring;

[0095] The above-mentioned plant parts are roots, stems, leaves, flowers, fruits, pollen or seeds.

[0096] The present application also provides a method for producing a commercial product, comprising obtaining the above-mentioned plant or plant part thereof, and producing the commercial product from the plant or plant part thereof, wherein the commercial product is selected from the group consisting of: a crude extract, a raw material drug, and / or a pharmaceutical preparation containing at least one of baccatin III and its derivatives, paclitaxel and its derivatives, taxane and its derivatives, docetaxel and its derivatives, and cabazitaxel and its derivatives.

[0097] Compared with the prior art, the present invention has the following beneficial effects:

[0098] (1) The present application provides a taxane C4-C20 oxetane-forming enzyme TOT, identifying a new, key biosynthetic enzyme that can catalyze the oxidation of carbon-carbon double bonds in taxane molecules to oxetanes and oxirane. This significantly advances the progress of elucidating the biosynthetic pathways of paclitaxel and other related compounds having oxetane ring groups or oxirane ring groups, and also greatly reduces the difficulty of completely elucidating the synthetic pathways of compounds such as paclitaxel. This lays a solid foundation for cell culture production of paclitaxel and reducing the production costs of compound drugs such as paclitaxel, and is expected to effectively solve the current situation of high prices and insufficient supply of paclitaxel drugs on the market.

[0099] (2) The nucleotide sequence encoding the taxane C4-C20 oxetane-forming enzyme TOT provided in this application provides a new genetic resource for increasing the production of paclitaxel and other related compounds having an oxetane ring group or an oxirane ring group and completing their synthetic pathways. This nucleotide sequence can be used for genetic engineering and metabolic engineering strategies to transform chassis hosts and produce drugs such as paclitaxel and their intermediates, etc., and has significant economic and social value. BRIEF DESCRIPTION OF THE DRAWINGS

[0100] Figure 1 shows the results of characterizing the activity of TOT1 in tobacco;

[0101] Wherein, a is the extracted ion chromatography (EIC) result of transiently expressing TOT in tobacco and catalyzing compound (1). Compared with the control, TOT can convert compound (1) into two new products, compound (2) and compound (3);

[0102] b is the structural formula of the three compounds: standard compound (1), compound (2), and compound (3).

[0103] Figures 2a and 2b show the activity comparison results of key amino acid mutations of the taxane C4-C20 oxetane-forming enzyme TOT;

[0104] Among them, Figure 2a shows the difference between the wild type (TOT WT ) compared to the fold difference in the production of compound (2) from compound (1) transformed by different mutants;

[0105] Figure 2b shows the difference between the WT Compared with the difference fold of compound (3) produced by transforming compound (1) by different mutants, mutants with a difference fold between the upper and lower dashed lines are considered to have no significant difference from the wild type.

[0106] FIG3 shows the extracted ion chromatography (EIC) results of yeast expressing TOT and feeding compound (1). Compared with the control, the taxane C4-C20 oxetane-forming enzyme TOT can convert compound (1) into two new products, compound (2) and compound (3);

[0107] FIG4 shows the extracted ion chromatography (EIC) results of insect cells expressing TOT and catalyzing compound (1). Compared with the control, the taxane C4-C20 oxetane-forming enzyme TOT can convert compound (1) into two new products, compound (2) and compound (3).

[0108] FIG5 shows the activity differences between different homologous genes of the taxane C4-C20 oxetane-forming enzyme TOT;

[0109] Wherein, a represents the fold difference in the content of compound (2) produced by other homologous genes transforming compound (1) compared with TOT1;

[0110] b shows the fold difference of compound (3) produced by transforming compound (1) with other homologous genes compared with TOT1.

[0111] FIG6 shows a comparison of the conversion efficiency of different taxane C4-C20 oxetane-forming enzyme TOT homologous genes on different compounds, and the oxidation activity of TOT1 on compound (1), compound (5), compound (6) and compound (7);

[0112] wherein a represents the structural formula of the two compounds used, compound (1) and compound (4);

[0113] b represents the content of oxidation products produced by TOT1 and TOT3 catalyzing compound (1) and compound (4), respectively, expressed as ion abundance;

[0114] c represents the structural formula of compound (1), compound (5), compound (6) and compound (7);

[0115] d represents the extracted ion chromatographic results of two oxidation products produced by TOT-catalyzed compound (1) and compound (5), respectively;

[0116] e shows the extracted ion chromatographic results of the oxidation products produced by TOT-catalyzed compounds (6) and (7). DETAILED DESCRIPTION

[0117] This application discloses enzymes, nucleic acid molecules, biomaterials, and their applications for catalyzing the formation of ternary or quaternary oxygen heterocyclic structures in taxane molecules. Those skilled in the art can refer to the disclosure herein and appropriately modify process parameters to achieve these goals. It is particularly important to note that all similar substitutions and modifications readily apparent to those skilled in the art are considered encompassed by this application. The methods and applications of this application have been described through preferred embodiments. It is apparent that those skilled in the art can modify, alter, and combine the methods and applications described herein to implement and apply the technology of this application without departing from the content, spirit, and scope of this application.

[0118] Explanation of terms:

[0119] In the present application, the term "TOT" may refer to taxane C4-C20 oxetane-forming enzyme, or a taxane C4-C20 oxetane-forming enzyme gene, or a nucleotide sequence encoding a taxane C4-C20 oxetane-forming enzyme, and the specific meaning may be determined in combination with the context.

[0120] In this application, the term "biological enzyme" or "enzyme" is a protein (or "polypeptide" or "peptide composition") with biological activity, including both naturally occurring proteins and variants and modified forms thereof. As used herein, the terms "protein" and "polypeptide" are used interchangeably, so the term polypeptide can be used to refer to a full-length polypeptide or a fragment of a full-length polypeptide. The term "fragment" refers to a portion of a polypeptide sequence. "Fragments" or "biologically active portions" include polypeptides that contain a sufficient number of contiguous amino acid residues to retain biological activity, such as polypeptides in which the N-terminal amino acid is truncated.

[0121] "Variant" means a substantially similar sequence. As will be readily understood by those skilled in the art, naturally occurring proteins may have some differences between different species or samples, which may be deletions and / or additions of one or more amino acids at one or more internal sites and / or substitutions of one or more amino acids at one or more sites of a natural polypeptide. However, this does not affect the same or similar effects, and these proteins may be referred to as natural variants of exemplary proteins. Modified forms of proteins include, but are not limited to, appropriate amino acid substitutions / additions / deletions that do not affect the biological activity of the target protein, truncated N-terminal amino acids, codon optimization suitable for host cell preferences, additions of tags, fusions, etc. These proteins may be referred to as artificial variants of reference proteins. Guidance for appropriate amino acid substitutions that do not affect the biological activity of the target protein can be found in the model of Dayhoff et al. (1978) Atlas of Protein Sequence and Structure (Natl. Biomed. Res. Found., Washington, DC), which is incorporated herein by reference. Conservative substitutions, such as replacing one amino acid with another amino acid having similar properties, may be optimal.

[0122] In this application, the term "amino acid" refers to any amino acid (both standard and non-standard amino acids), including but not limited to α-amino acids, β-amino acids, γ-amino acids and δ-amino acids. Examples of suitable amino acids include but are not limited to alanine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan and valine.

[0123] As used herein, the term "taxane C4-C20 oxetane-forming enzyme" refers to an enzyme that catalyzes the oxidation of carbon-carbon double bonds in taxane molecules to oxetanes and oxirane. The term "TOT" may refer to a taxane C4-C20 oxetane-forming enzyme, a taxane C4-C20 oxetane-forming enzyme gene, or a nucleotide molecule or sequence encoding a taxane C4-C20 oxetane-forming enzyme. The specific meaning of the term "TOT" can be determined based on the context.

[0124] In some embodiments, the enzymes of interest herein can be isolated from materials containing the enzymes from any source. Any method for obtaining the enzymes of interest herein is compatible with the present invention.

[0125] As used herein, the term "isolated" means removed from its natural environment, or from other compounds present when the compound is first formed. The term "isolated" includes material isolated from a natural source as well as material recovered following preparation by recombinant expression in a host cell (e.g., nucleic acids and proteins), or chemically synthesized compounds, such as nucleic acid molecules, proteins, and peptides.

[0126] As used herein, the term "nucleic acid molecule" (or "nucleic acid" or "polynucleotide") may refer to a polymeric form of nucleotides, which may include sense and antisense strands of RNA, cDNA, genomic DNA, as well as synthetic forms and mixed polymers of the above. Nucleotides may refer to ribonucleotides, deoxyribonucleotides, or modified forms of either type of nucleotide. As used herein, "nucleic acid molecule" is synonymous with "nucleic acid" and "polynucleotide." A nucleic acid molecule is typically at least 10 bases in length, unless otherwise indicated. The term may refer to RNA or DNA molecules of indefinite length. The term includes single-stranded and double-stranded forms of DNA. Nucleic acid molecules may include one or both of naturally occurring and modified nucleotides linked together by naturally occurring and / or non-naturally occurring nucleotide linkages.

[0127] As will be readily appreciated by those skilled in the art, for nucleotide sequences, well-known molecular biology techniques, such as the polymerase chain reaction (PCR) and hybridization techniques outlined herein, can be used to identify naturally occurring variants, ie, substantially similar sequences.

[0128] As will be readily appreciated by those skilled in the art, nucleic acid molecules may be chemically or biochemically modified, or may comprise non-natural or derivatized nucleotide bases. Such modifications include, for example, labeling, methylation, substitution of one or more naturally occurring nucleotides with analogs, internucleotide modifications (e.g., uncharged bonds: such as methyl phosphonates, phosphotriesters, phosphoramidites, carbamates, etc.; charged bonds: such as phosphorothioates, phosphorodithioates, etc.; pendant moieties: such as peptides; intercalators: such as acridine, psoralen, etc.; chelating agents; alkylating agents; and modified bonds: such as α-anomeric nucleic acids, etc.). The term "nucleic acid molecule" also includes any topological conformation, including single-stranded, double-stranded, partially double-stranded, triple-stranded, hairpin, circular, and padlock conformations.

[0129] In some embodiments, the nucleic acid molecules associated with the present application can be cloned from DNA comprising a given nucleic acid molecule from any source, for example, by PCR amplification and / or restriction enzyme digestion. In some embodiments, the nucleic acid molecules associated with the present application are synthetic. Any method for obtaining the nucleic acid molecules associated with the invention is compatible with the present application.

[0130] In this application, the term "identity" refers to sequence similarity to a natural nucleic acid sequence or amino acid sequence. Identity can be evaluated by the naked eye or with computer software. Using computer software, the identity between two or more sequences can be expressed as a percentage (%), which can be used to evaluate the identity between related sequences.

[0131] Unless otherwise indicated, the sequence identity values ​​provided herein refer to the values ​​obtained using the full-length sequences of the present application by Jalview version 2.11.2.7 (Waterhouse, AM, Procter, JB, Martin, DMA, Clamp, M. and Barton, GJ (2009) "Jalview Version 2-a multiple sequence alignment editor and analysis workbench" Bioinformatics 25(9)1189-1191 doi:10.1093 / bioinformatics / btp033) using the default parameters in the multiple alignment software package MUSCLE v3.8.31 ("MUSCLE: multiple sequence alignment with high accuracy and high throughput" Nucleic Acids Res. 32(5):1792 (2004)); or any equivalent program thereof).

[0132] In this application, the term "homology" is sometimes used to refer to the level of similarity between two or more nucleic acid or amino acid sequences (i.e., sequence similarity or identity) expressed as a percentage of positional identity. Homology also refers to the concept of evolutionary relatedness, typically demonstrated by similar functional properties between different nucleic acids or proteins that share similar sequences.

[0133] As those skilled in the art will readily appreciate, homologous sequences can be obtained by comparing known sequences with genomic or transcriptomic data from samples of evolutionarily closely related species. For example, between different species of the same genus or between different strains of the same species, by comparing a known sequence with the genomic or transcriptomic data of a sample, those skilled in the art can anticipate that the sequence has the same or similar function.

[0134] Other mathematical algorithms are known in the art and can be used to align two sequences. See, for example, the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264, as modified in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877. This algorithm was incorporated into the BLAST program of Altschul et al. (1990) J. Mol. Biol. 215:403. BLAST nucleotide searches can be performed using the BLASTN program (nucleotide query for nucleotide sequence searches) to obtain nucleotide sequences homologous to the nucleic acid molecules of the present application, or using the BLASTX program (translated nucleotide query for protein sequence searches) to obtain protein sequences homologous to the nucleic acid molecules of the present application. BLAST protein searches can be performed using the BLASTP program (protein query for protein sequence searches) to obtain amino acid sequences homologous to the protein molecules of the present application, or using the TBLASTN program (protein query for translated nucleotide sequence searches) to obtain nucleotide sequences homologous to the protein molecules of the present application. In order to obtain gap alignments for comparison purposes, Gapped BLAST (in BLAST2.0) can be used as described in Altschul et al. (1997) Nucleic Acids Res. 25:3389. Alternatively, PSI-Blast can be used to perform an iterative search that detects distant relationships between molecules. See Altschul et al. (1997) supra. When utilizing BLAST, Gapped BLAST, and PSI-Blast programs, the default parameters of the corresponding programs (e.g., BLASTX and BLASTN) can be used. Alignment can also be performed manually by inspection.

[0135] In this application, the term "synthetic" refers to polynucleotide (i.e., DNA or RNA) molecules produced by chemical synthesis as an in vitro process. For example, TM Synthetic DNA is produced during the reaction process in the tube so that the synthetic DNA is enzymatically produced from natural DNA or RNA chains. Other laboratory methods can be used to synthesize polynucleotide sequences. Oligonucleotides can be chemically synthesized on an oligonucleotide synthesizer using solid phase synthesis using phosphoramidites. The synthesized oligonucleotides can be annealed to each other as complexes to produce "synthetic" polynucleotides. Other methods for chemically synthesizing polynucleotides are known in the art and can be easily implemented for use in the present disclosure.

[0136] In this application, the term "gene" is defined as a unit of inheritance (usually represented by a DNA sequence) that occupies a specific position in a chromosome and contains the genetic instructions that contribute to the potential phenotypic characteristics or traits of a plant. In some scenarios, the term "gene" refers to a nucleic acid molecule that expresses a specific protein. A "gene" includes DNA regions that encode a gene product, as well as all DNA regions that regulate the production of the gene product, regardless of whether such regulatory sequences are adjacent to coding and / or transcribed sequences. Thus, a gene includes, but is not necessarily limited to, promoter sequences, terminators, translation regulatory sequences such as ribosome binding sites and internal ribosome entry sites, enhancers, silencers, insulators, boundary elements, replication origins, matrix attachment sites, introns, and locus control regions.

[0137] As used herein, the term "gene product" refers to any product produced by a gene. For example, a gene product can be a direct transcriptional product of a gene (e.g., mRNA, tRNA, rRNA, antisense RNA, interfering RNA, ribozyme, structural RNA, or any other type of RNA), or a protein produced by translation of an mRNA.

[0138] In this application, the term "expression cassette" refers to a DNA fragment that can be inserted into a nucleic acid or polynucleotide at a specific restriction site or by homologous recombination. As used herein, the DNA fragment comprises a polynucleotide encoding a polypeptide of interest, and the expression cassette and restriction sites are designed to ensure that the expression cassette is inserted into an appropriate reading frame for transcription and translation. In one embodiment, the expression cassette can include a polynucleotide encoding a polypeptide of interest and, in addition to the polynucleotide, also has elements that promote specific host cell transformation. In one embodiment, the expression cassette can also include elements that allow the expression of the polynucleotide encoding the polypeptide of interest to be enhanced in the host cell. These elements can include, but are not limited to, promoters, minimal promoters, enhancers, response elements, terminator sequences, polyadenylation sequences, etc.

[0139] In this application, the terms "vector" and "construct", "cloning vector" and "expression vector" are used interchangeably, and mean a vector that can introduce a DNA or RNA sequence (e.g., an exogenous gene) into a host cell to transform the host and promote the expression (e.g., transcription and translation) of the introduced sequence. "Non-viral vector" refers to any vector that does not comprise a virus or retrovirus. In some embodiments, a "vector" is a DNA sequence that comprises at least one DNA replication origin and at least one selective marker gene. Examples include, but are not limited to, plasmids, cosmids, phages, bacterial artificial chromosomes (BACs) or viruses that carry exogenous DNA into cells. Vectors can also include one or more genes, antisense molecules and / or selective marker genes and other genetic elements known in the art. Vectors can transduce, transform or infect cells, thereby causing cells to express nucleic acid molecules and / or proteins encoded by the vector.

[0140] In this application, the term "expression" refers to the biosynthesis of a gene product, including the transcription and / or translation of the gene product. "Expressing" or "producing" a protein or polypeptide from a DNA molecule refers to transcribing and translating the coding sequence to produce the protein or polypeptide, while "expressing" or "producing" a protein or polypeptide from an RNA molecule refers to translating the RNA coding sequence to produce the protein or polypeptide.

[0141] Expression vectors containing all necessary expression elements are commercially available and are well known to those skilled in the art. See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, 1989. Cells are genetically engineered by introducing exogenous DNA (RNA) into the cells. The exogenous DNA (RNA) is placed under the effective control of transcriptional elements to allow expression of the exogenous DNA in the host cell.

[0142] As used herein, the term "transformation" includes all techniques by which a nucleic acid molecule can be introduced into such a cell. Examples include, but are not limited to, transfection with viral vectors; transformation with plasmid vectors; electroporation; adipose infection; microinjection; Agrobacterium-mediated transfer; direct DNA uptake; WHISKERS TM Transgenic plants are characterized by transgenic genes, including genomic DNA-mediated transformation and microprojectile bombardment. These techniques can be used for both stable and transient transformation of plant cells. "Stable transformation" refers to the introduction of a nucleic acid fragment into the genome of a host organism, resulting in genetic stability. Once stably transformed, the nucleic acid fragment is stably integrated into the genome of the host organism and any subsequent generations. Host organisms containing the transformed nucleic acid fragment are referred to as "transgenic" organisms. "Transient transformation" refers to the introduction of a nucleic acid fragment into the nucleus or DNA-containing organelles of a host organism, resulting in gene expression without genetically stable inheritance.

[0143] In some embodiments, to transform hosts and host cells, the nucleotide sequences of the present application can be inserted into any vector known in the art that is suitable for expressing nucleotide sequences in hosts or host cells using standard techniques. The choice of vector depends on the preferred transformation technique and the target host species to be transformed. The transformation method depends on the host cell to be transformed, the stability of the vector used, the expression level of the gene product, and other parameters.

[0144] In this application, the term "stringent conditions" may refer to any of low, moderate, and high stringency conditions. "Low stringency conditions" include, for example, 5×SSC, 5×Denhardt's solution, 0.5% SDS, 50% formamide, and 32°C. "Moderate stringency conditions" include, for example, 5×SSC, 5×Denhardt's solution, 0.5% SDS, 50% formamide, and 42°C. "High stringency conditions" include, for example, 5×SSC, 5×Denhardt's solution, 0.5% SDS, 50% formamide, and 50°C. Among the above conditions, increasing the temperature increases the likelihood of obtaining DNA with high homology. Hybridization stringency can be affected by a variety of factors, including temperature, probe concentration, probe length, ionic strength, time, and salt concentration. Those skilled in the art can achieve similar stringency conditions by appropriately selecting these factors.

[0145] Chinese and English comparison:

[0146] In the above descriptions of the figures and the following examples, the Chinese and English names of the compounds are as follows:

[0147] Table 1 Chinese-English comparison table

[0148] Table 2 Amino acid sequence similarity of TOT enzyme

[0149] Table 3 Nucleotide sequence similarity of TOT enzyme

[0150] The reagents, instruments, strains or other biological materials used in this application can be obtained through commercial channels.

[0151] The present application is further described below with reference to the embodiments:

[0152] Example 1. Expression of Taxane C4-C20 Oxetane-Forming Enzyme TOT Gene in Tobacco

[0153] 1. cDNA Acquisition

[0154] Taxus chinensis var. maire was preserved in the laboratory. Young leaves were collected and immediately frozen in liquid nitrogen. A portion of the sample was ground in a mortar and pestle, and 100 mg was added to a 1.5 mL centrifuge tube. Lysis buffer was added, and RNA was extracted (Plant Total RNA Isolation Kit Plus, FOREGENE, China). mRNA was reverse transcribed into cDNA using a reverse transcription kit (HiScript III 1st Strand cDNA Synthesis Kit, Vazyme, China).

[0155] 2. Cloning of Taxane C4-C20 Oxetane-Forming Enzyme TOT

[0156] The genome of Taxus chinensis was analyzed, and 83 genes of the CYP725A subfamily of Taxus chinensis were obtained. The nucleotide sequence and amino acid sequence of the TOT1 reading frame were shown in SEQ ID NO: 1 (its homologous sequences are shown in SEQ ID NO: 2 to 24 in the sequence listing) and SEQ ID NO: 25 (its homologous sequences are shown in SEQ ID NO: 26 to 48 in the sequence listing), respectively. The names of the biological enzymes corresponding to the homologous sequences are TOT2 to TOT24, respectively.

[0157] The sequence of SEQ ID NO: 1 is as follows:

[0158] The sequence of SEQ ID NO: 25 is as follows:

[0159] Based on the nucleotide sequence of the TOT gene, primers P1 and P2 were designed to amplify the TOT gene. These primers contain a portion of the sequence of the tobacco expression vector pEAQ-HT. Using cDNA from Taxus chinensis leaves as a template, the TOT gene was amplified by PCR. The PCR product was recovered by gel excision and recombined with the linearized pEAQ-HT vector digested with RruI and XhoI. The recombinant plasmid was cloned and sequenced using the ClonExpress One-Step Cloning Kit (Novagen). The positive recombinant plasmid was designated pEAQ-HT-TOT.

[0160] Among the primers used, P1 and P2 were used to amplify TOT, and the primer sequences are shown in Table 4.

[0161] Table 4 Primer sequences Note: The lowercase nucleotide sequence is the vector sequence, and the uppercase nucleotide sequence is the TOT-specific primer sequence.

[0162] 3. Functional Verification of the Taxane C4-C20 Oxetane Forming Enzyme TOT Gene in Tobacco

[0163] The constructed expression vector pEAQ-HT-TOT was transformed into Agrobacterium GV3101 to obtain the GV3101 / pEAQ-HT-TOT transgenic strain; a positive single clone was picked and inoculated into LB medium (containing 50 μg / mL kanamycin and 25 μg / mL rifampicin) and cultured at 28°C for 24 h; the cultured bacterial liquid was taken and diluted in 10 mL LB medium (containing 50 μg / mL kanamycin and 25 μg / mL rifampicin) at a ratio of 1:100 and cultured at 28°C overnight until the OD 600 Add resuspension MMA (10mM MES, 10mM MgCl2, 150μM acetosyringone) to the final OD 600 The viscosity is 0.8-1.0, and it is allowed to stand at room temperature for 1-2 hours.

[0164] The resuspended Agrobacterium GV3101 (containing the TOT gene) was injected into the underside of 4-6 week-old Nicotiana benthamiana leaves using a 1 mL syringe with the needle removed. After drying under light for 1-2 hours, the leaves were transferred to a dark place for incubation for 24 hours, and then transferred to normal light for incubation. Fourteen days after the injection of Agrobacterium GV3101, an aqueous solution of taxadiene-hexol-hexaacetate (compound (1)) was injected into the leaves injected with Agrobacterium GV3101 and incubated for another 24 hours. Leaves injected with GFP were used as controls.

[0165] The tobacco sample was ground with a grinder, and the sample powder was transferred to a 15 mL centrifuge tube. After freeze-drying, dichloromethane and methanol (DCM / MeOH = 1:1) were added, and ultrasonic extraction was performed for 5 minutes. The sample was concentrated using a vacuum concentrator to remove the solvent. After adding 500 μL of methanol, it was shaken thoroughly. After the solid was dissolved, it was centrifuged at 12000 rpm at room temperature for 15 minutes, loaded, and detected by LC-MS.

[0166] As shown in FIG1 , TOT can convert compound (1) into two isomers, namely 1-dehydroxybaccatin IV (compound (2)) and baccatin I (compound (3)).

[0167] Example 2. Activity screening of taxane C4-C20 oxetane-forming enzyme TOT gene mutants

[0168] 1. Construction of a Taxane C4-C20 Oxetane-Forming Enzyme TOT Mutant

[0169] Using the recombinant plasmid pEAQ-HT-TOT as a template, point mutation primers were designed (Table 4). After amplifying the plasmid containing the TOT gene with high-fidelity PCR, a plasmid with an amino acid point mutation was obtained. After ligation, transformation, and sequencing, the plasmid was extracted. The TOT gene containing the point mutation was amplified using a high-fidelity enzyme and constructed into the tobacco expression vector pEAQ-HT using the ClonExpress homologous recombination cloning kit (Ultra One Step Cloning Kit) to obtain the recombinant plasmid pEAQ-HT::TOTsm. The recombinant plasmid was then transformed into Agrobacterium GV3101 to obtain GV3101 / pEAQ-HT-TOTsm transgenic Agrobacterium. Agrobacterium containing pEAQ-HT::TOT1 was used as a control strain.

[0170] 2. Functional Verification of the Taxane C4-C20 Oxetane Forming Enzyme TOT Mutant in Tobacco

[0171] A positive single colony of Agrobacterium was picked and inoculated into LB medium (containing 50 μg / mL kanamycin and 25 μg / mL rifampicin) and cultured at 28°C for 24 h; the cultured bacterial liquid was diluted in 10 mL LB medium (containing 50 μg / mL kanamycin and 25 μg / mL rifampicin) at a ratio of 1:100 and cultured at 28°C overnight until OD 600 Add resuspension MMA (10mM MES, 10mM MgCl2, 150μM acetosyringone) to the final OD 600 The viscosity is 0.8-1.0, and it is allowed to stand at room temperature for 1-2 hours.

[0172] The resuspended Agrobacterium (containing the TOTsm mutant gene) was injected into the underside of 4-6 week-old Nicotiana benthamiana leaves using a 1 mL syringe with the needle removed. After drying under light for 1-2 hours, the leaves were transferred to a dark place for incubation for 24 hours and then transferred to normal light for incubation. Four days after the injection of Agrobacterium, the aqueous solution of compound (1) was injected into the leaves injected with Agrobacterium and incubated for another 24 hours.

[0173] The tobacco sample was ground with a grinder and the sample powder was transferred to a 15 mL centrifuge tube. After freeze-drying, dichloromethane and methanol (DCM / MeOH = 1:1) were added and ultrasonically extracted for 5 minutes. The sample was concentrated using a vacuum concentrator, the solvent was removed, 500 μL of methanol was added, and the sample was fully shaken. After the solid was dissolved, the sample was centrifuged at 12000 rpm for 15 minutes at room temperature and loaded for detection in LC-MS. The 1-dehydroxybaccatin IV (compound (2)) and baccatin I (compound (3)) produced by different mutants of TOT in tobacco were compared with the wild type (WT) based on the ion intensity. The obtained ion intensity difference multiple results are shown in Figures 2a and 2b.

[0174] The results of activity comparison showed (Figure 2a and Figure 2b):

[0175] Different TOT mutants have different effects on their enzyme activity. For the oxetane product, mutants such as V237A, P167A, Q187A, Q6A, V129A, I172A, S314A, V319A, Q381A, E313A, V205A, R50A, S500A, P428A, H249A, S310A, K259A, R269A, M177A, and D361A will lead to a significant increase in the content of 1-dehydroxybaccatin IV, indicating that optimizing the amino acids at these sites can improve TOT enzyme activity. The conversion efficiency of TOT to compound (2) was significantly improved, while mutants such as S442A, F122A, L329A, F446A, R450A, G448A, P454A, W369A, G384A, P492A, W133A, I400A, R158A, P445A, R430A, F491A, R451A, R387A, E343A, E374A, Q405A, and C453A resulted in a decrease in the yield of compound (2) or even undetectable yields, indicating that these sites are crucial for maintaining the activity of TOT;

[0176] For the oxirane products, mutants such as S314A, V382A, I347A, V237A, S500A, V371A, Q381A, P167A, H249A, V205A, R50A, G448A, P454A, M177A, K259A, E313A, R269A, P490A, I285A, Q187A, Q6A, V129A, I172A, T410A, T231A, K360A, V319A, G455A, and K94A increased the content of compound (3) produced by TOT, which also indicates that further modification of these sites Optimization can improve the activity of TOT, especially the enzymatic efficiency of converting the C4-C20 double bond to produce a three-membered ring, while mutants such as I385A, P492A, F426A, W369A, F443A, Y367A, R430A, F446A, F122A, G384A, M452A, R387A, P445A, W133A, E343A, R158A, L330A, I400A, F491A, R377A, R451A, E374A, Q405A, and C453A will reduce the activity of TOT in catalyzing compound (1) to produce 3, or even make TOT lose its catalytic ability.

[0177] Therefore, amino acid sites such as V237, P167, Q187, Q6, V129, I172, S314, V319, Q381, E313, V205, R50, S500, P428, H249, S310, K259, R269, M177, D361, V382, I347, V371, G448, P454A, P490, I285, T410, T231, K360, G455, and K94 play an important role in improving the activity of TOT. Further optimization at these sites is likely to obtain highly active mutants, thereby enabling substrates containing C4-C20 double bonds to be more efficiently converted into oxetane or oxirane products, making the precursor more efficiently converted into paclitaxel, and better It is used in the modification of the total synthesis pathway of paclitaxel, and the amino acid sites I385, S442, F122, L329, F446, R450, G448, P454, W369, G384, P492, W133, I400, R158, P445, R430, F491, R451, R387A, E343, E374, Q405, C453, F426, F443, Y367, M452, L330, and R377 play an important role in maintaining the catalytic activity of TOT, especially sites such as E374, Q405, and C453, which can determine whether TOT has catalytic activity. Therefore, these sites need to be paid special attention to in the subsequent optimization and should not be easily mutated into amino acids such as alanine that reduce or lose their activity.

[0178] Example 3. Construction of engineered strains and methods for producing 1-dehydroxybaccatin IV and baccatin I

[0179] 1. Construction of Yeast Engineering Strains

[0180] The chassis engineering yeast strain was WAT11 (MATa leu2-3,112 trp1-1 can1-100 ura3-1 ade2-1 his3-11,15). Primers P3 and P4 were designed, and the recombinant plasmid pEAQ-HT-TOT was used as a template to amplify the TOT gene using PrimeSTAR high-fidelity enzyme PCR. The construct was then inserted into the galactose-inducible yeast expression vector pESC-Leu (containing the Taxus cytochrome P450 reductase TcCPR gene) under the GAL1 promoter using the ClonExpress homologous recombination cloning kit (Ultra One Step Cloning Kit) to obtain the recombinant plasmid pESC-Leu::TOT. The recombinant plasmid was further introduced into the chassis strain WAT11 using the PEG / LiAc method to obtain the engineered strain WAT11 / TOT producing 1-dehydroxybaccatin IV and baccatin I. At the same time, the control engineered strain WAT11 / pESC-Leu was obtained by introducing the empty vector pESC-Leu.

[0181] PCR gene-specific primers are shown in Table 4.

[0182] 2. Method for producing 1-dehydroxybaccatin IV and baccatin I by fermentation with engineered bacteria

[0183] One single clone of Saccharomyces cerevisiae engineered strain WAT11 / TOT was selected and inoculated into 30 mL of SD-Leu liquid medium containing 2% glucose, and cultured overnight at 28°C and 250 rpm in a shaker. 600Yeast solution was added to 50 mL of YPGA medium at a ratio of 1:1 / 100 mL of YPGA medium (10 g yeast extract, 20 g peptone, 74 mg adenine sulfate, 100 mL glucose solution (200 g / L), and the volume was adjusted to 1 L with water), and the culture was carried out at 28°C and 250 rpm in a shaker for 30 h. The cells were collected by centrifugation at 5000 × g for 5 minutes, washed three times with 50 mL of sterile deionized water, and resuspended in 50 mL of induction medium YPLA (10 g yeast extract, 20 g peptone, 74 mg adenine sulfate, 100 mL galactose solution (200 g / L), and the volume was adjusted to 1 L with water), and the culture was carried out at 28°C and 250 rpm in a shaker for 16 h. 10 mL of the bacterial solution was centrifuged at 5000 × g for 5 minutes, and 500 μL The cells were resuspended in YPLA medium, and compound (1) at a final concentration of 50 μM and 4% DMSO were added. The cells were cultured for 24 h, and ethyl acetate was added. The cells were ultrasonically extracted for 30 min and centrifuged at 10,000 rpm for 10 min at room temperature. The supernatant was retained and the extraction was repeated once. The supernatant liquids were combined and vacuum dried, and then redissolved in methanol for LC-MS analysis.

[0184] The LC-MS results showed (Figure 3) that the engineered bacteria fermentation produced two products similar to those in the tobacco expression system, whose retention times corresponded to 1-dehydroxybaccatin IV and baccatin I, respectively, thus corroborating the results of the tobacco expression system.

[0185] Example 4. Insect cells express taxane C4-C20 oxetane-forming enzyme TOT and catalyze the formation of oxetanes and oxirane from the C4-C20 double bond of taxane.

[0186] 1. Plasmid Construction

[0187] The insect cells used are Sf9 cells, which are a clone of Sf21 cells developed from the ovarian tissue of the pupal stage of Spodoptera frugiperda. Using the recombinant plasmids PEAQ-HT-TOT and PEAQ-HT-CPR as templates, primers P5 and P6, and primers P7 and P8 were designed, respectively. The TOT and CPR (cytochrome P450 reductase) genes were amplified using PimeSTAR high-fidelity PCR. The recombinant plasmids were then inserted into the insect cell expression vector pFastBac1 under the polyhedrin promoter using the ClonExpress Ultra One Step Cloning Kit to obtain the recombinant plasmids pFastBac1-TOT and PEAQ-HT-CPR. The recombinant plasmids were then transformed into the Escherichia coli DH10Bac strain containing the baculovirus shuttle vector Bacmid and a helper plasmid (for expressing the transposase protein required for transposition) to obtain the recombinant plasmids Bacmid-TOT and Bacmid-CPR. A control strain Bacmid was also obtained by introducing the control vector pFastBac1.

[0188] Among the primers used, P5 and P6 were used to amplify TOT, and P7 and P8 were used to amplify CPR. The primer sequences are shown in Table 4.

[0189] 2. Activity Assay of TOT Protein Expressed in Insect Cells

[0190] Bacmid-TOT1, Bacmid-CPR and Bacmid were transfected into insect cells Sf9 using linearized polyethyleneimine (PEI) transfection reagent. After 3 days of culture, P1 virus was obtained. P1 virus was transfected into Sf9 cells to obtain P2 virus. Repeat the experiment to obtain P4 virus. Bacmid-TOT, Bacmid-CPR and Bacmid P4 virus were used to infect 50 mL of Sf9 suspension cells, respectively. After 2 days of culture at 100 rpm at 28 ° C, the cells were centrifuged at 100g for 5 minutes at room temperature, and resuspended with 500 μL of supernatant. Compound (1) with a final concentration of 50 μM and 4% DMSO were added. The cells were cultured for another 24 hours, and ethyl acetate was added. Ultrasonic extraction was performed for 30 minutes. The cells were centrifuged at 10,000 rpm for 10 minutes at room temperature. The supernatant was retained. After repeated extraction, the supernatant was combined and vacuum dried, then re-dissolved in methanol and analyzed by LC-MS.

[0191] The LC-MS results showed (Figure 4) that TOT expressed in insect cells was also able to convert compound (1) into compound (2) and compound (3), whose retention times corresponded to 1-dehydroxybaccatin IV and baccatin I, respectively, thus corroborating the results of the tobacco and yeast expression systems.

[0192] Example 5. Comparison of the activities of the taxane C4-C20 oxetane-forming enzyme TOT and its homologous genes

[0193] 1. Construction of a Taxane C4-C20 Oxetane-Forming Enzyme TOT Homologous Gene

[0194] Based on the nucleotide sequences of TOT homologous genes (TOT2 / 3 / 4), primers P9 and P10, P11 and P12, and P13 and P14 were designed. These primers contain a portion of the tobacco expression vector pEAQ-HT sequence. Using cDNA from Taxus chinensis leaves as a template, TOT2 / 3 / 4 genes were amplified by PCR. The PCR products were recovered by gel excision and recombined with the linearized pEAQ-HT vector digested with RruI and XhoI. The recombinant plasmids were cloned and sequenced using the ClonExpress One-Step Cloning Kit (Novagen). The positive recombinant plasmids were designated pEAQ-HT-TOT2, pEAQ-HT-TOT3, and pEAQ-HT-TOT4, respectively. The recombinant plasmids were transformed into Agrobacterium tumefaciens GV3101, resulting in transgenic Agrobacterium GV3101 / pEAQ-HT-TOT2 / 3 / 4. Agrobacterium containing pEAQ-HT::TOT1 was used as a control strain.

[0195] Among the primers used, P9 and P10 were used to amplify TOT2, P11 and P12 were used to amplify TOT3, and P13 and P14 were used to amplify TOT4. The primer sequences are shown in Table 4.

[0196] 2. Comparison of the activity of the taxane C4-C20 oxetane-forming enzyme TOT and its homologous genes in tobacco

[0197] A positive single colony of Agrobacterium was picked and inoculated into LB medium (containing 50 μg / mL kanamycin and 25 μg / mL rifampicin) and cultured at 28°C for 24 h; the cultured bacterial liquid was diluted in 10 mL LB medium (containing 50 μg / mL kanamycin and 25 μg / mL rifampicin) at a ratio of 1:100 and cultured at 28°C overnight until OD 600 Add resuspension MMA (10mM MES, 10mM MgCl2, 150μM acetosyringone) to the final OD 600 The viscosity is 0.8-1.0, and it is allowed to stand at room temperature for 1-2 hours.

[0198] The resuspended Agrobacterium (containing TOT1 / 2 / 3 / 4 genes) was injected into the underside of leaves of 4-6 week-old Nicotiana benthamiana using a 1 mL syringe without the needle. After drying under light for 1-2 hours, the leaves were transferred to a dark place for incubation for 24 hours and then transferred to normal light for incubation. Four days after the injection of Agrobacterium, the aqueous solution of compound (1) was injected into the leaves injected with Agrobacterium and incubated for another 24 hours.

[0199] The tobacco sample was ground with a grinder and the sample powder was transferred to a 15 mL centrifuge tube. After freeze-drying, dichloromethane and methanol (DCM / MeOH = 1:1) were added and ultrasonically extracted for 5 minutes. The sample was concentrated using a vacuum concentrator, the solvent was removed, 500 μL of methanol was added, and the sample was fully shaken. After the solid was dissolved, the sample was centrifuged at 12,000 rpm for 15 minutes at room temperature and loaded for detection in LC-MS. Based on the ion intensity, 1-dehydroxybaccatin IV (compound (2)) and baccatin I (compound (3)) produced by different homologous genes of TOT in tobacco were compared with TOT1 respectively. The obtained ion intensity difference multiple results are shown in Figure 5.

[0200] The results of the activity comparison of the taxane C4-C20 oxetane-forming enzyme TOT and its homologous genes showed that compared with TOT1, the difference in the content of the four-membered ring product compound (2) produced by TOT2, TOT3, and TOT4 was not obvious, while the difference in the content of the three-membered ring product compound (3) was quite obvious, especially TOT3, which could significantly increase the yield of the three-membered ring product compound (3).

[0201] Example 6. Comparison of the catalytic activity of taxane C4-C20 oxetane-forming enzyme TOT and its homologous genes towards different taxane types

[0202] 1. Construction of a Taxane C4-C20 Oxetane-Forming Enzyme TOT Homologous Gene

[0203] Same as Example 5.

[0204] 2. Functional characterization of the taxane C4-C20 oxetane-forming enzyme TOT and its homologous genes in tobacco

[0205] A positive single colony of Agrobacterium was picked and inoculated into LB medium (containing 50 μg / mL kanamycin and 25 μg / mL rifampicin) and cultured at 28°C for 24 h; the cultured bacterial liquid was diluted in 10 mL LB medium (containing 50 μg / mL kanamycin and 25 μg / mL rifampicin) at a ratio of 1:100 and cultured at 28°C overnight until OD 600 Add resuspension MMA (10mM MES, 10mM MgCl2, 150μM acetosyringone) to the final OD600 The viscosity is 0.8-1.0, and it is allowed to stand at room temperature for 1-2 hours.

[0206] The resuspended Agrobacterium (containing the TOTsm mutant gene) was injected into the underside of 4-6 week-old Nicotiana benthamiana leaves using a 1 mL syringe with the needle removed. After drying under light for 1-2 hours, the leaves were transferred to a dark place for incubation for 24 hours and then transferred to normal light for incubation. Four days after the injection of Agrobacterium, an aqueous solution of compound (1) or taxadiene-2α,5α,7β,9β,10β,13α-hexanol-5α-acetate (compound (4)) was injected into the leaves injected with Agrobacterium and incubated for another 24 hours.

[0207] The tobacco samples were ground using a grinder, and the sample powder was transferred to a 15 mL centrifuge tube. After freeze-drying, dichloromethane and methanol (DCM / MeOH = 1:1) were added, and ultrasonic extraction was performed for 5 minutes. The samples were concentrated using a vacuum concentrator, the solvent was removed, 500 μL of methanol was added, and the samples were shaken thoroughly. After the solids were dissolved, the samples were centrifuged at 12000 rpm for 15 minutes at room temperature and loaded for detection by LC-MS. The quantitative results of the oxidation products formed by tobacco-expressed TOT1 or TOT3 catalyzing compound (1) or compound (4) are shown in Figures 6a and b. The results of the oxidation products formed by tobacco-expressed TOT1 catalyzing compound (1), compound (5), compound (6), and compound (7) are shown in Figures 6c, d, and e.

[0208] The results showed that both TOT1 and TOT3 could catalyze compound (1) and compound (4) to produce oxidation products. In general, TOT1 and TOT3 catalyzed the oxidation products (m / z 659[M+Na] + ) has a higher conversion efficiency, while the catalytic compound (4) forms an oxidation product (m / z 449[M+Na] + ) has a lower catalytic efficiency. At the same time, it can be found that the catalytic efficiency of TOT3 for both compounds is higher than that of TOT1.

[0209] In addition, TOT1 can catalyze compound (1) and compound (5) to form two monooxidized products containing oxetane and ethylene oxide, respectively. When the compound lacks the C5 acetyl group, TOT1 can also catalyze the corresponding compound. For example, TOT1 can catalyze compound (6) or compound (7) to form an oxidation product.

[0210] In summary, the present application provides a taxane C4-C20 oxetane-forming enzyme TOT that catalyzes the carbon-carbon double bond at the C4-C20 position of taxane to form oxetanes and oxirane, laying the foundation for further comprehensive analysis of the taxol biosynthesis pathway. At the same time, the present application provides a yeast engineered strain WAT11 / TOT and insect-expressed TOT, and finds I385, S442, F122, L329, F446, R450, G448, P454, W369, G384, P492, W133, I400, R158, P445, R430, F491, R451, R387, E343, E374, Q405, C453, F Amino acids 426, F443, Y367, M452, L330, and R377 are essential for maintaining TOT activity, while amino acid sites such as V237, P167, Q187, Q6, V129, I172, S314, V319, Q381, E313, V205, R50, S500, P428, H249, S310, K259, R269, M177, D361, V382, I347, V371, G448, P454, P490, I285, T410, T231, K360, G455, and K94 are essential for the conversion of substrate to the four-membered ring product 1-dehydroxybaccatin IV. The improvement of the conversion efficiency of III or paclitaxel plays an important role and can be better applied to the transformation and optimization of the synthetic pathways of paclitaxel and other related compounds with oxetane ring groups or oxirane ring groups, which has significant economic and ecological value.

[0211] The above is only a preferred embodiment of the present application. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present application. These improvements and modifications should also be regarded as the scope of protection of the present application.

Claims

1. A biological enzyme, characterized in that It includes at least one of the following sequences: a1) the amino acid sequence shown in SEQ ID NO: 25; a2) a fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of the amino acid sequence shown in SEQ ID NO: 25; a3) a protein having the same function obtained by replacing and / or deleting and / or adding one or more amino acid residues of the amino acid sequence shown in SEQ ID NO: 25; a4) A protein having at least 60% homology to the amino acid sequence shown in SEQ ID NO: 25 and having the same function.

2. The biological enzyme according to claim 1, characterized in that The protein in a3) is a mutant of the amino acid sequence shown in a1), and the mutant includes at least one of V237A, P167A, Q187A, Q6A, V129A, I172A, S314A, V319A, Q381A, E313A, V205A, R50A, S500A, P428A, H249A, S310A, K259A, R269A, M177A, D361A, V382A, I347A, V371A, G448A, P454AA, P490A, I285A, T410A, T231A, K360A, G455A, and K94A mutants.

3. The biological enzyme according to claim 1, characterized in that In a4), the amino acid sequence having at least 60% homology with the amino acid sequence shown in SEQ ID NO: 25 and having the same function includes at least one of the amino acid sequences shown in SEQ ID NO: 26-48.

4. A nucleic acid molecule encoding the biological enzyme according to any one of claims 1 to 3, characterized in that: It includes at least one of the following sequences: b1) the nucleotide sequence shown in SEQ ID NO: 1; b2) a complementary sequence, a degenerate sequence or a homologous sequence of the nucleotide sequence shown in SEQ ID NO: 1, wherein the homologous sequence is a nucleotide sequence having at least 75% homology with the nucleotide sequence shown in SEQ ID NO: 1; b3) A nucleotide sequence that hybridizes with the nucleotide sequence shown in b1) or b2) under stringent conditions and is capable of encoding a protein with the same function.

5. The nucleic acid molecule according to claim 4, characterized in that b2), the homologous sequence includes at least one of the nucleotide sequences shown in SEQ ID NOs: 2 to 24.

6. A biomaterial, characterized in that The biological material is any one of the following c1) to c4): c1) an expression cassette containing the nucleic acid molecule according to claim 4 or 5; c2) a vector containing the nucleic acid molecule according to claim 4 or 5 or the expression cassette according to c1); c3) a recombinant microorganism containing at least one of the above-mentioned gene, c1) expression cassette, and c2) recombinant vector; c4) Recombinant plant cells and / or recombinant animal cells containing at least one of the above-mentioned gene, c1) expression cassette, and c2) recombinant vector.

7. The biomaterial according to claim 6, characterized in that The microorganisms include bacteria and / or fungi; The plant cells include at least one of tobacco cells, yew cells, artemisia annua cells, Arabidopsis cells, Physcomitrella patens cells, liverwort cells, tomato cells, ginseng cells, cotton cells, sugarcane cells, potato cells, corn cells, wheat cells, rice cells, radish cells, lettuce cells, and algae cells; The animal cells include at least one of insect cells, mammalian cells, nematode cells, and fish cells.

8. A method for producing a host cell, the method comprising transforming the host cell with at least one of the nucleic acid molecule of claim 4 or 5, the expression cassette in the biological material of claim 6 or 7, or a vector.

9. A method for producing a plant or a plant cell, the method comprising transforming the plant or the plant cell with at least one of the nucleic acid molecule of claim 4 or 5, the expression cassette in the biological material of claim 6 or 7 or the vector.

10. A method for producing the biological enzyme according to any one of claims 1 to 3, characterized in that: The host cell is transformed with at least one of the nucleic acid molecule according to claim 4 or 5, or the expression cassette or vector in the biological material according to claim 6 or 7, so that the host cell expresses the biological enzyme.

11. Use of any one of the biological enzymes according to any one of claims 1 to 3, the nucleic acid molecules according to claim 4 or 5, or the biological materials according to claim 6 or 7 in synthesizing oxygen-containing heterocyclic compounds, characterized in that: The oxygen-containing heterocyclic compound includes a compound having an oxetane ring group and / or a compound having an oxirane ring group.

12. The use according to claim 11, characterized in that: The compound having an oxetane ring group includes a taxane compound, and / or an intermediate thereof; Preferably, the taxane compound includes at least one of paclitaxel and its derivatives, docetaxel and its derivatives, cabazitaxel and its derivatives; Preferably, the taxane compound intermediate includes at least one of 1-dehydroxybaccatin IV and its derivatives, baccatin III and its derivatives, and 10-deacetylbaccatin III and its derivatives.

13. The use according to claim 11 or 12, characterized in that: The compound having an oxirane ring group includes at least one of baccatin I and its derivatives, analogs of Taxumairol C and its derivatives, and Taxuchin A and its derivatives.

14. A method for synthesizing an oxygen-containing heterocyclic compound in vivo or in vitro, characterized in that: Using a taxane compound containing 5α-acetoxy-4,20-alkenyl or a taxane compound containing 5α-hydroxy-4,20-alkenyl as a substrate, under the catalysis of the biological enzyme according to any one of claims 1 to 3, synthesizing an oxygen-containing heterocyclic compound; The oxygen-containing heterocyclic compound includes a compound having an oxetane ring group and / or a compound having an oxirane ring group.

15. The method according to claim 14, characterized in that The substrate comprises at least one of taxadiene-hexol-hexaacetate, taxadiene-2α,5α,7β,9β,10β,13α-hexol-5α-acetate, 5α-acetate-Taxuspine F, taxadiene-hexol-tetraacetate, and Taxuspine F.

16. The method according to claim 14 or 15, characterized in that The in vivo includes inside a microorganism, inside an algae cell, inside a plant cell and / or inside an animal cell.

17. The method according to any one of claims 14 to 16, characterized in that: The in vivo synthesis of oxygen-containing heterocyclic compounds comprises: allowing the nucleic acid molecule of claim 3 to express a biological enzyme in a microbial cell, an algae cell, a plant cell and / or an animal cell; using a taxane compound containing a 5α-acetoxy-4,20-alkenyl group or a taxane compound containing a 5α-hydroxy-4,20-alkenyl group as a substrate, and synthesizing the oxygen-containing heterocyclic compound under the catalytic action of the biological enzyme.

18. A plant or a plant part thereof, characterized in that The plant is one of the following: (d1) A transgenic plant containing the nucleic acid molecule according to claim 4 or 5; (d2) a plant grown from the plant cell of claim 6 or 7; (d3) A plant obtained by the method of claim 9; (d4) progeny formed by self-pollination of any plant in (d1) to (d3), and plants grown from the progeny; (d5) offspring formed by hybridization of any plant in (d1) to (d3) with other varieties, and plants grown from the offspring; The above-mentioned plant parts are roots, stems, leaves, flowers, fruits, pollen or seeds.

19. A method of producing a commercial product, comprising obtaining the plant or plant part thereof as claimed in claim 18, and producing the commercial product from the plant or plant part thereof; Preferably, the commercial product is selected from the group consisting of: a crude extract, a raw material and / or a pharmaceutical preparation containing at least one of baccatin III and its derivatives, paclitaxel and its derivatives, taxane and its derivatives, docetaxel and its derivatives, cabazitaxel and its derivatives.

Citation Information

Patent Citations

  • Biological enzyme for catalyzing formation of taxane molecule ternary or quaternary oxygen heterocyclic structure, gene, biological material and application of biological enzyme, gene and biological material

    CN117070480A

  • Taxoid-14-beta-hydroxylases and methods for their use

    US20030166176A1